Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Ninety One UK Ltd

Ninety One UK Ltd raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.2% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 569,045 shares of the medical research company's stock after acquiring an additional 61,655 shares during the quarter. Ninety One UK Ltd owned approximately 0.15% of Thermo Fisher Scientific worth $283,157,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMO. Brighton Jones LLC grew its position in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares in the last quarter. Bank Pictet & Cie Europe AG grew its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after buying an additional 461 shares in the last quarter. Proficio Capital Partners LLC grew its position in shares of Thermo Fisher Scientific by 32.1% during the 4th quarter. Proficio Capital Partners LLC now owns 1,466 shares of the medical research company's stock worth $763,000 after buying an additional 356 shares in the last quarter. Finally, Isthmus Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 152.3% during the 4th quarter. Isthmus Partners LLC now owns 1,438 shares of the medical research company's stock worth $748,000 after purchasing an additional 868 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $13.65 during trading on Wednesday, hitting $412.52. 630,331 shares of the company traded hands, compared to its average volume of 1,977,669. The stock's 50-day simple moving average is $409.11 and its 200 day simple moving average is $478.29. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The company has a market cap of $155.72 billion, a PE ratio of 24.33, a P/E/G ratio of 2.23 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the business earned $5.11 earnings per share. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.42%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TMO. Argus decreased their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Finally, Royal Bank Of Canada decreased their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $601.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.